A migraine is a neurological condition marked by intense, throbbing headaches—often on one side of the head—accompanied by symptoms such as nausea, vomiting, and sensitivity to light, sound, or smells.
Discover potential treatment options for moderate or severe migraine, with or without aura.
You might be eligible for this study.
Migraines affect more than 39 million Americans, disrupting their daily lives with throbbing or pulsating pain often accompanied by nausea, vomiting, and sensitivity to light, sound, or smells. While early intervention remains key, new therapies are being explored to improve migraine management.
At Hightower Clinical, we are currently running clinical trials focused on acute migraine to evaluate the safety and efficacy of a study drug in people as a potential acute migraine treatment option.
Participation in the clinical trial is entirely voluntary and free of charge.
To participate, fill out the form, and a member of our research staff will call you to discuss your eligibility for the Clinical Research Study.
Study Name | Protocol Number | Sponsor |
---|---|---|
Acute Migraine | KAL-K304-P001 | Kallyope |
In collaboration with pharmaceutical companies, Hightower Clinical is conducting a research study focused on evaluating an investigational treatment for acute migraine in people with moderate and severe unilateral headaches.
This Phase 2 acute migraine clinical trial aims to determine whether the investigational drug can effectively relieve migraine pain two hours after dosing and reduce other symptoms such as nausea, vomiting, and sensitivity to sound, light, and smell.
Participants will be randomly assigned to one of two groups: one that will receive the investigational drug and another that will receive a placebo.
All study procedures and related treatments, including investigational medication, are provided at no cost, and insurance is not required for participation.
The study doctor will guide you through every step of the clinical trial before you decide to participate and will answer any questions you have about the study treatment.
Upon agreeing to participate in the acute migraine study, you will be asked to sign an Informed Consent Form that provides comprehensive details about the trial. Our research team will guide you through the study process and explain your role in the trials. We encourage participants to ask any questions they may have before deciding to participate or withdraw from the trial.
Once the consent form is signed and all inquiries are addressed, participants will be randomly assigned to one of two groups: the Control group or the Experimental group.
In the Control group, participants receive a placebo medication, while the Experimental group receives the study drug. This study utilizes a double-blind design, meaning that neither the researcher nor the participant knows which treatment is being administered.
All study-related care is provided at no cost. Expert physicians and healthcare professionals will conduct thorough physical exams and assessments throughout the trial.
18-70 years
All
Acute Migraine
Recruiting
Acute migraines are intense, often debilitating headaches that strike suddenly and can last from a few hours to several days. They are usually characterized by throbbing pain on one side of the head, often accompanied by nausea, sensitivity to light and sound, and visual disturbances known as aura. Unlike chronic migraines, which occur frequently, acute migraines are episodic and may be triggered by stress, hormonal changes, certain foods, or lack of sleep.
A migraine is a neurological condition marked by intense, throbbing headaches—often on one side of the head—accompanied by symptoms such as nausea, vomiting, and sensitivity to light, sound, or smells.
While the exact cause is unknown, migraines are believed to result from abnormal brain activity affecting nerve signals, chemicals, and blood vessels. Common triggers include stress, hormonal changes, certain foods, sleep disturbances, and environmental factors.
Acute migraines occur occasionally, with fewer than 15 headache days per month. Chronic migraines happen more frequently—15 or more days per month—and may require long-term management.
Participants are evaluated for eligibility and, if accepted, are randomly assigned to receive either the investigational treatment or a placebo. Throughout the study, they are monitored closely through check-ins, symptom tracking, and health assessments. All study-related care is provided at no cost.
By participating, you gain access to potential new treatment options before they become widely available. You’ll also be helping researchers advance migraine care for others while receiving expert medical oversight during the trial.